MedTrace Logo

Sertraline in Addition to Standard of Care Treatment for Coccidioidomycosis

NCT02908334 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2022-03-21

No results posted yet for this study

Summary

In this study patients will be randomized 1:2 to receive either standard of care treatment or standard of care + Sertraline 200mg/day for 2 weeks, then 400 mg/day for 50 weeks for treatment of disseminated and meningeal coccidioidomycosis.

Conditions

  • Coccidioidomycosis

Interventions

DRUG

Sertraline

400 mg/day sertraline

Sponsors & Collaborators

Principal Investigators

  • Simon Paul, MD · UCSF - Fresno

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-30
Primary Completion
2019-01-22
Completion
2019-01-22

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02908334 on ClinicalTrials.gov